MSB 1.34% $1.51 mesoblast limited

Cell Therapy News/Articles, page-16089

  1. 500 Posts.
    lightbulb Created with Sketch. 251

    11 Billion for this pipeline would make MSB's estimated valuation rather large by comparison.


    Prometheus Biosciences therapeutic pipeline


    ProgramIndicationPreclinicalPhase 1Phase 2Phase 3
    PRA023
    TL1A mAb
    Ulcerative Colitis




    Crohn's Disease




    SSc-ILD




    PRA052*
    CD30 ligand mAb
    Immune-Mediated Diseases




    PR1100
    Cytokine receptor mAb
    Immune-Mediated Diseases




    PR2100
    Inflammatory cytokine mAb
    Immune-Mediated Diseases




    PR300
    GPCR small molecule
    Immune-Mediated Diseases




    *Partnered with Dr. Falk Pharma in Europe, Australia, and New Zealand


    https://hotcopper.com.au/data/attachments/5311/5311670-82bba025b606eb1d7341ca39ba576ad3.jpg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.